Increased resistance to apoptosis is a hallmark of many tumor cells. The functional inhibition of specific antiapoptotic factors may provide a rational basis for the development of novel therapeutic strategies. We investigated here whether the RNA interference (RNAi) technology could be used to increase the apoptotic susceptibility of cancer cells. As a molecular target, we chose the antiapoptotic livin (ML-IAP, KIAP) gene, which is expressed in a subset of human tumors. We identified vector-borne small interfering (si)RNAs, which could efficiently block endogenous livin gene expression. Silencing of livin was associated with caspase-3 activation and a strongly increased apoptotic rate in response to different proapoptotic stimuli, such as doxorubicin, UVirradiation, or TNFa. The effects were specific for Livinexpressing tumor cells. Our results (i) provide direct evidence that the intracellular interference with livin gene expression resensitizes human tumor cells to apoptosis, (ii) define the livin gene as a promising molecular target for therapeutic inhibition, and (iii) show that the livin gene is susceptible to efficient and specific silencing by the siRNA technology.
Introduction
Cancer cells are often characterized by increased resistance to apoptosis (Igney and Krammer, 2002) , which enables their survival under abnormal growth stimulation and mediates their increased resistance to various forms of cellular stress, such as DNA damage, hypoxia, or nutrient deprivation (Evan and Vousden, 2001; Green and Evan, 2002) . Moreover, apoptosis deficiency is considered to be a major cause of the therapeutic resistance of tumors in the clinic, since many chemo-and radiotherapeutic agents act through the induction of apoptosis (Herr and Debatin, 2001; Johnstone et al., 2002) . It is therefore hoped that an increased understanding of the regulatory circuits contributing to the apoptosis resistance of cancer cells may provide a rational basis for the development of novel therapeutic strategies, for example, by specifically interfering with the activity of antiapoptotic factors in tumor cells (Nicholson, 2000; Herr and Debatin, 2001; Borkhardt, 2002; Johnstone et al., 2002; Reed, 2003) .
The inhibitor of apoptosis protein (IAP) family consists of a group of structurally related proteins with antiapoptotic properties Salvesen and Duckett, 2002) . A novel member of this family is the Livin/ML-IAP/KIAP protein (in the following termed Livin) Vucic et al., 2000; Ashhab et al., 2001; Kasof and Gomes, 2001) . In transfection analyses, it has been shown that ectopic expression of Livin can block apoptosis induction by a variety of proapoptotic stimuli. This appears to be mediated, at least in part, by inhibiting caspases-3 and -9 (Vucic et al., 2000; Kasof and Gomes, 2001 ). Interestingly, the livin gene exhibits a restricted expression pattern, since it has been found to be expressed in certain tumor cells, including melanoma or HeLa cervical carcinoma cells, but not, or to substantially lesser amounts in most normal adult tissues (Kasof and Gomes, 2001; Lin et al., 2000; Vucic et al., 2000; Ashhab et al., 2001; Gazzaniga et al., 2003) . Its expression in tumor cells suggests that Livin, as it is assumed for other IAPs (LaCasse et al., 1998; Salvesen and Duckett, 2002) , may contribute to tumorigenesis by causing apoptosis resistance. Consequently, inhibition of Livin expression may represent an interesting therapeutic strategy, in order to correct the apoptosis deficiency of tumor cells specifically.
RNA interference (RNAi) has emerged as a powerful new technique, allowing targeted post-transcriptional gene silencing in plants and animals (Fire et al., 1998; Hannon, 2002; McManus and Sharp, 2002) . In mammalian cells, sequence-specific inhibition of gene expression can be achieved by transfecting 19-21 nucleotide (nt) small interfering (si)RNAs, which are complementary to the mRNA sequence of a given target gene (Elbashir et al., 2001) . In order to circumvent the transient nature of transfected siRNAs and the requirements for their chemical synthesis, vector systems allowing the expression of siRNAs have been created most recently (summarized in Agami 2002; Paddison and Hannon, 2002; Tuschl, 2002) . A prototype vector system is exemplified by the plasmid pSUPER (Brummelkamp et al., 2002b) , which employs the polymerase-III (Pol-III) H1-RNA gene promoter to generate biologically active siRNAs from short oligonucleotides.
Apart from being a useful new strategy for the analysis of gene function at the intracellular level, the inhibition of defined genes by siRNAs has obvious therapeutic implications. In cancer biology, RNAi with antiapoptotic target genes may serve as a novel strategy to modulate the apoptosis deficiency of tumor cells. We demonstrate here that vector-derived siRNAs are powerful molecular tools to block the expression of the livin gene in tumor cells efficiently and specifically. This is associated with a strongly increased apoptosis rate following treatment with proapoptotic stimuli, including genotoxic agents used for cancer therapy. Thus, siRNAs that target the livin gene specifically lower the apoptotic threshold of tumor cells and bear the potential to augment the efficacy of currently available treatment regimens in cancer therapy.
Results
Two RNAi target regions, Livin-1 and Livin-2, were selected from the livin cDNA following the recommendations for the design of efficient siRNA sequences (Brummelkamp et al., 2002b; Elbashir et al., 2002, Paddison and Hannon, 2002) . Both sequences are present in the transcripts for the two known splice forms of Livin, Livin a (KIAP) and Livin b (ML-IAP) Vucic et al., 2000; Ashhab et al., 2001; Kasof and Gomes, 2001) . They were introduced into the pSUPER vector in the form of synthetic oligonucleotides, consisting of the respective 19 nt target sequences, separated by a 9 nt spacer from the reverse complement of the 19 nt target sequences, yielding pSUPER-Livin-1 and pSUPER-Livin-2. The predicted secondary structures of the plasmid-derived transcripts are depicted in Figure 1a .
HeLa cells were chosen for RNAi, since they express endogenous Livin protein ( Figure 1b ) and reproducibly exhibited high DNA transfection efficiencies of more than 85% following calcium phosphate coprecipitation (Chen and Okayama, 1987) . After transfection, both pSUPER-Livin-1 and pSUPER-Livin-2 siRNAs efficiently inhibited endogenous Livin protein expression (Figure 1c ). This was not observed for the transfection control pSUPER-Luc, which specifically silences the noncellular firefly Photinus pyralis luciferase gene ( Figure 1c and data not shown). In contrast to Livin, the amounts of cellular Tubulin protein were not affected by either pSUPER-Livin-1 or pSUPER-Livin-2 ( Figure 1c ). Similar to the results in HeLa cells, a specific downmodulation of endogenous Livin expression by pSUPER-Livin-2 was also observed in MeWo melanoma cells (data not shown). In further support of the fact that livin repression was caused by a specific siRNA effect, expression of both Livin-1 and Livin-2 siRNAs led to a clear reduction of livin transcripts in HeLa cells (Figure 1d ). Taken together, these results demonstrate that vector-borne siRNAs can specifically block livin gene expression in human cancer cells, with high efficiency.
Since pSUPER-Livin-2 regularly suppressed endogenous livin expression more strongly than pSUPERLivin-1 (Figure 1 ), the former was chosen for subsequent analyses. It has been reported that Livin inhibits caspase-3 activity following ectopic expression from heterologous promoters or in in vitro assays (Vucic et al., 2000; Kasof and Gomes, 2001) . In contrast to these investigations, the siRNA approach followed in this study should allow for analysis of the effects of endogenous Livin on cellular caspase-3 activity. As shown in Figure 2 , pSUPER-Livin-2 increased caspase-3-like activities in HeLa cells, thereby indicating that the downregulation of Livin expression is associated with a release of caspase-3 from negative regulation by Livin. This conclusion is corroborated by the observation that the caspase-3 inhibitor DEVD-fmk completely inhibited the increase of DEVD-cleavage following pSUPERLivin-2 transfection in HeLa cells (Figure 2 ). In further support for the specificity of the livin-targeting siRNAs, induction of caspase-3 activities by pSUPER-Livin-2 was observed in Livin-expressing HeLa cells, but not in H1299 cells (Figure 2 ), which do not express endogenous Livin protein ( Figure 1b) .
Next, we investigated whether Livin-2 siRNA can sensitize Livin-positive cells to proapoptotic stimuli. As shown in Figure 3 following treatment of HeLa cells with doxorubicin, UV-irradiation, and TNFa, when compared with control-transfected cells (pSUPER-Luc). These events were associated with promoted cleavage of the caspase substrate poly(ADP-ribose) polymerase (PARP) for all three proapoptotic agents, as indicated by the increase in the faster migrating PARP cleavage product, in the presence of pSUPER-Livin-2. Under the same experimental conditions, we did not observe a differential effect of pSUPER-Livin-2 on caspases-7, -8, and -9 expression patterns, when compared with controltransfected cells.
In order to analyse the cellular consequences of siRNA-mediated silencing of the livin gene, TdTmediated dUTP biotin nick-end labeling (TUNEL) analyses were performed, which allow for the detection of apoptotic cells (Figure 4a ). In the absence of a proapoptotic stimulus, the number of TUNEL-positive cells increased approximately twofold following expression of pSUPER-Livin-2 (Figures 4a, b) , thereby indicating that siRNA directed against livin modestly increases the spontaneous apoptosis rate of HeLa cells in transient transfections. However, apoptosis stimulated by doxorubicin, UV-irradiation, and TNFa was strongly increased by pSUPER-Livin-2 (Figures 4a, b ). These results demonstrate that siRNA directed against livin can efficiently sensitize Livin-positive cancer cells towards proapoptotic stimuli.
In order to corroborate the notion that this effect was specifically due to siRNA-mediated targeting of the livin gene, we constructed expression vector pLivinbMT. It contains a mutant livin-b cDNA that bears nine silent mutations (i.e. mutations that do not alter the Livin-b protein sequence) within the target region for pSUPERLivin-2. In contrast to the efficient inhibition of Livin-b expression from the wild-type cDNA, pSUPER-Livin-2 did not affect the expression of Livin-b protein from pLivinbMT ( Figure 4c) . Notably, following transfection and subsequent UV-irradiation of HeLa cells, pLivinbMT efficiently reverted the pSUPER-Livin-2-mediated increase in apoptotic cells back to the level of control transfectants (Figure 4c ). This phenotypic rescue by an siRNA-refractory livin cDNA variant further demonstrates that the proapoptotic sensitization by pSUPER-Livin-2 is due to the specific targeting of the livin gene.
Colony formation assays were performed in order to analyse the effects of stable transfection of pSUPERLivin-2 on the growth of tumor cells. To this end, HeLa cervical carcinoma, MeWo melanoma cells, and H1299 lung cancer cells were transfected with either pSUPERLivin-2 or control vector pSUPER-Luc. In addition, pSV2Neo (Southern and Berg, 1982) was cotransfected, to allow for the selection of transfected cells by neomycin resistance. As shown in Figure 5a , pSU-PER-Livin-2 had a strong inhibitory effect on Livinexpressing HeLa cells, efficiently abolishing their colony formation capacity, when compared to control transfectants. This effect was specific for Livin-expressing cells, since it was also observed in MeWo cells, but not in H1299 cells (Figure 5a ). In addition, HeLa cells stably transfected with pSUPER-Livin-2 exhibited a massive induction of apoptosis when compared to controltransfected cells, as visualized by a strong reduction in cell numbers, increased chromatin condensation, and a positive TUNEL assay (Figure 5b ). These results show that the selection for stable pSUPER-Livin-2 transfectants resulted in the specific cell death of Livinexpressing cancer cells, through induction of apoptosis.
Discussion
The specific interference with factors contributing to the apoptosis resistance of tumor cells may provide a novel basis for the development of rational intervention strategies in cancer therapy (Nicholson, 2000; Herr and Debatin, 2001; Johnstone et al., 2002; Reed, 2003) . Notably, agents inducing apoptosis could bear a great therapeutic advantage over agents inducing reversible growth inhibition, since the former may not require a continuous application. In an attempt to correct the apoptosis deficiency of tumor cells by RNAi, we chose the livin gene as a molecular target since (i) the antiapoptotic potential of livin could contribute to the apoptosis-resistant phenotype of cancer cells and (ii) its preferential expression in tumors could make livin an interesting therapeutic target for tumor-specific intervention strategies. We show here that the siRNA technology represents an extremely powerful tool in order to inhibit endogenous livin gene expression and to modulate specifically the apoptosis resistance of Livinexpressing tumor cells.
In this study, we observed that inhibition of livin gene expression was associated with a strongly increased apoptotic response in the presence of several proapoptotic agents, indicating that the interference with livin leads to a sensitization to proapoptotic stimuli. This observation is in line with experiments showing that the inhibition of other IAPs with inhibitory peptides derived from the cellular SMAC protein, a negative regulator of IAPs (Du et al., 2000; Verhagen et al., 2000) , potentiated the effects of proapoptotic stimuli (Fulda et al., 2002) . However, whereas SMAC and SMAC-derived peptides also have the potential to inhibit Livin function (Vucic et al., 2002) , it should be noted that they can also inhibit a variety of additional IAP family members which, in part, are ubiquitously expressed (Verhagen and Vaux, 2002) . This approach therefore conceptionally differs from the highly sequence-specific siRNA strategy followed here, which affects only Livin-expressing cells.
In accordance with our observations at the cellular level, siRNA-mediated silencing of endogenous Livin expression led to an increase in the concentration of the active form of caspase-3, a main effector caspase for the induction of apoptotic cell death (Slee et al., 1999) , and increased cleavage of the caspase substrate PARP. This is in agreement with in vitro data indicating that the Livin protein can act as an inhibitor of caspase-3 (Vucic et al, 2000; Kasof and Gomes, 2001) . Under conditions of caspase-3 activation and PARP cleavage, we did not detect cleavage of procaspase-9. This upstream caspase has been found to interact with Livin in vitro (Vucic et al, 2000; Kasof and Gomes, 2001 ); however, proteolytic processing is not necessarily required for its activation (Stennicke et al., 1999) . More work is necessary in order to delineate the upstream events leading to caspase-3 activation in detail. Notably, Livin has also been reported to possess caspase-independent antiapoptotic activities through activation of the mitogen-activated protein (MAP) kinase JNK-1 (Sanna et al., 2002) . The efficacy of siRNAs to silence expression of a given gene can vary, depending on the half-life and abundance of the gene product as well as on the mRNA target sequence and its accessibility (Elbashir et al., 2001 (Elbashir et al., , 2002 Agami, 2002; McManus and Sharp, 2002; Paddison and Hannon, 2002, Wilde et al., 2002) . For siRNA design, the 19 nt mRNA target sequence should preferentially contain approximately 50% GC content and should be flanked by 5 0 -AA and 3 0 -UU residues (Brummelkamp et al., 2002b; Elbashir et al., 2002) . Both siRNA sequences identified in this study were found to inhibit livin gene expression substantially, both at the RNA and protein level. Interestingly, the degree of gene silencing was regularly more pronounced for Livin-2 than for Livin-1, despite the fact that the former is flanked by a 3 0 -GU motif in the livin mRNA, instead of the preferred UU sequence.
In order to corroborate the notion that the biological effects observed in this study were due to RNAi, we investigated whether the induced phenotype could be rescued by re-expression of the target gene. Indeed, Livin expression from a cDNA construct that was refractory to inhibition by pSUPER-Livin-2 efficiently reverted the proapoptotic sensitization of HeLa cells. This further supports the notion that the sensitization to proapoptotic stimuli is mechanistically due to the specific inhibition of endogenous livin gene expression by RNAi.
Apart from providing new powerful tools for the analysis of gene function at the intracellular level, inhibitory siRNAs could bear great potential to serve as a basis for the development of novel therapeutic strategies (Agami, 2002; Borkhardt, 2002; Brummelkamp et al., 2002a; Paddison and Hannon, 2002) . As shown here, the short-term expression of livin-targeting siRNAs by transient transfection augmented the apoptotic response of tumor cells towards different proapoptotic stimuli, including doxorubicin, a drug that is widely used for cancer therapy in the clinic. Thus, in view of a clinical perspective, a combination treatment of livin-targeting siRNAs with proapoptotic drugs, such as chemo-or radiotherapeutic agents, appears to be most promising.
Our data, obtained from transient transfection analyses, indicate that short-term interference with livin resulted, per se, only in a modest increase of the apoptotic rate, despite highly efficient inhibition of Livin protein expression. This differs from a study in which the complete livin cDNA was expressed for 24 h in antisense orientation and marked induction of apoptosis was reported (Kasof and Gomes, 2001) . Interestingly, however, we also observed that the stable transfection of an expression vector generating siRNA against livin selectively inhibited the outgrowth of Livin-expressing tumor cells in colony formation assays, with high efficiency. This suggests that a longer exposure to agents interfering with livin function may suffice to induce apoptotic cell death, even in the absence of additional proapoptotic stimuli.
Despite their therapeutic potential, major technical hurdles still have to be overcome, in order to apply siRNAs as drugs. Vector-borne expression of siRNAs can efficiently inhibit the function of target genes in vivo (Xia et al., 2002) but, under therapeutic aspects, will have to meet the general challenges of gene therapy approaches, such as efficient delivery into the target cells or the circumvention of immune responses. Notably, recent in vivo studies showed that siRNAs could be directly applied to organs of postnatal mice by high pressure injection into the tail vein, leading to the specific inhibition of target genes (Lewis et al., 2002; McCaffrey et al., 2002; Song et al., 2003) . Although it is questionable whether the hydrodynamic injection technique used in these studies is applicable to primates (Song et al., 2003) , these data show that a direct application of active siRNAs via the bloodstream is principally feasible. In addition, alternative delivery strategies could be envisioned: translocating peptides have been developed, which efficiently transport plasmid DNA into living cells (Morris et al., 2000; Rittner et al., 2002) ; other peptides were found to introduce compounds into all cell layers of intact human skin (Rothbard et al., 2000 (Rothbard et al., , 2002 . It remains to be seen whether the further development of these techniques may also provide a new route for the topical application of siRNA-encoding vectors in order to treat lesions of the skin and mucosa.
Materials and methods

Oligonucleotides and plasmids
Synthetic double-stranded oligonucleotides with the following sequences were introduced into vector pSUPER (Brummelkamp et al., 2002b) : 5 0 -GTGGTTCCCCAGCTGTCAGttcaagagaCTGACAGCTGGGGAACCAC-3 0 (for Livin-1) and 5 0 -GGAAGAGACTTTGTCCACAttcaagagaTGTGGACAA AGTCTCTTCC-3 0 (for Livin-2). They consist of 19 nt sequences derived from the livin gene (nucleotide positions 611-629 for Livin-1 and 648-666 for Livin-2, numbering according to Kasof and Gomes, accession number AF311388), which are separated by a 9 nt linker (lower case letters) from the reverse complement of the same 19 nt sequence. For negative control pSUPER-Luc, double-stranded oligonucleotide 5 0 -CATCACGTACGCGGAATACttcaagagaGTATTCC-GCGTACGTGATG-3 0 , which contains a 19 nt sequence complementary to the P. pyralis (variant GL3) luciferase gene, was introduced into pSUPER.
Expression vector pLivinbWT expresses the complete Livinb cDNA from pcDNA3 (Invitrogen, Karlsruhe, Germany). pLivinbMT contains a mutant livin b cDNA that was generated by introducing nine silent mutations into the target region for pSUPER-Livin-2, by PCR-mediated site-directed mutagenesis (Butz and Hoppe-Seyler, 1993) , changing the sequence from ggaagagactttgtccacagt (nts 648-668) to ggCagGgaTttCgtGcaTTCC (mutated nucleotides are indicated in capital letters).
Transfections, treatment with proapoptotic agents, and colony formation assays HeLa, MeWo, and H1299 cells were maintained in Dulbecco's minimal essential medium (pH 7.2), supplemented with 10% fetal calf serum. Exponentially growing HeLa cells were transfected by calcium-phosphate co-precipitation (Chen and Okayama, 1987) , yielding transfection efficiencies of over 85%, as assessed by transfecting a green fluorescent proteinproducing vector (not shown). In transient transfections, cells were harvested 48 h after transfection for protein, caspase activity, and TUNEL analyses (see below). For the treatment with proapoptotic agents, cells were exposed 36 h post transfection to a single dose of 50J/m 2 UV-irradiation (Stratalinker 2400, Stratagene, Heidelberg, Germany), or to 0.5 mg/ml doxorubicin (Sigma, Taufkirchen, Germany), and harvested 12 h later. TNFa (Strathmann Biotec, Hamburg, Germany) was applied for 2 h at a concentration of 1000 U/ml, in the presence of cycloheximide (Sigma), 46 h after transfection.
For colony formation assays, cells were transfected with either pSUPER-Livin-2 or pSUPER-Luc, together with pSV2Neo (Southern and Berg, 1982) , and stably transfected cells were selected by neomycin resistance, in the presence of 1 mg/ml Geneticin (Invitrogen). After 6-10 days selection, colonies were fixed with formaldehyde and stained with crystal violet.
RNA and protein analyses
For Northern blot analyses, poly-A þ -RNA was isolated using the Dynabeads mRNA DirectTM kit (Dynal, Oslo, Norway) according to the instructions provided by the manufacturer. Livin transcripts were detected using the complete radiolabeled livin-a cDNA (Ashhab et al., 2001 ) as a probe. Glycerylaldehyde-3-phosphate dehydrogenase (GAPDH) served as a control probe in order to monitor equal loading between individual lanes.
Protein extracts were prepared essentially as described (Butz et al., 1999) . For Western blot analyses, approximately 30 mg of protein were separated by 12.5% SDS-PAGE (except for PARP analysis, where 10% SDS-PAGE was employed), transferred to an Immobilon-P membrane (Millipore, Bedford, USA), and analysed by enhanced chemiluminescence (Amersham, Braunschweig, Germany) using monoclonal anti-Livin antibody IMG347 (Biocarta Europe, Hamburg, Germany); monoclonal anti-Tubulin antibody Ab-1 (Oncogene, Boston, USA), polyclonal rabbit anti-caspase-3 antibody Pab CM1 (BD Biosciences, Heidelberg, Germany), monoclonal anticaspase-7 antibody (BD Biosciences), monoclonal anti-caspase-8 antibody (BD Biosciences), polyclonal rabbit anticaspase-9 antibody (BD Biosciences), and mouse monoclonal anti-poly(ADP-ribose) polymerase antibody C2-10 (BD Biosciences).
Caspase and TUNEL assays
To detect caspase-3-like protease activities, the ApoAlert Caspase-3 Colorimetric Assay Kit (Clontech, Palo Alto, USA) was used. Cytosolic lysates were prepared 48 h following transfection and incubated with 50 mm p-nitroanilide (pNA) conjugated to the caspase cleavage site Asp-Glu-Val-Asp (DEVD) for 1 h at 371C. Hydrolysed pNA was detected using a Multiscan MS colorimeter (ThermoLabsystems, Vantaa, Finland) at 405 nm. For control experiments, the lysates were incubated with 10 mm of the caspase-3 inhibitor DEVD-fmk (Clontech) for 30 min, before addition of the substrate.
For apoptosis detection, cells were grown on coverslips and TUNEL analyses were performed using the in situ cell death detection kit (Roche Molecular Biochemicals), as previously described (Butz et al., 2000) . Total DNA was stained with 4 0 ,6-diamidino-2-phenylindole (DAPI, Roche Molecular Biochemicals). Apoptotic strand breaks and total DNA were visualized by transmission epifluorescence microscopy.
